Cancer. 2026 Sep 1;132(17):e70584. doi: 10.1002/cncr.70584.

ABSTRACT

BACKGROUND: Cancer statistics for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually aggregated, masking substantial variation within this heterogeneous population. Herein, the American Cancer Society reports cancer incidence and survival for 8 Asian American and 3 NHPI ethnic groups.

METHODS: The authors used population-based cancer registry data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program, for Asian American and NHPI ethnic groups from 2000 through 2022.

RESULTS: During 2018-2022, overall cancer incidence ranged from 218.3 per 100,000 Kampuchean people to 474.5 per 100,000 Native Hawaiian people, which was 1.5 times higher than the rate for the aggregated Asian American and NHPI population (307.3 per 100,000). High incidence among Native Hawaiian people is largely driven by the highest rates of female breast, colorectal, and prostate cancers, whereas infection-related cancers were highest among Asian American ethnic groups. For example, liver and stomach cancer incidence is highest among Vietnamese (22.2 per 100,000) and Korean people (17.8 per 100,000), respectively, both of which were nearly twice that in Native Hawaiian people (12.9 and 9.6 per 100,000, respectively). Native Hawaiian and Samoan women are twice and 3 times as likely, respectively, to be diagnosed with uterine corpus cancer as aggregated Asian American and NHPI women or White women. Five-year relative survival ranges from 42% in Laotians to 74% in Asian Indians/Pakistanis, with largest differences for colorectal (43% in Laotians to 72% in Asian Indians/Pakistanis) and prostate (63% in Kampucheans to 97% in Japanese) cancers.

CONCLUSIONS: Wide variation in cancer risk within the Asian American and NHPI population highlights the critical need for disaggregated data to effectively target cancer prevention and control interventions.

PMID:42658095 | DOI:10.1002/cncr.70584

The post Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026 appeared first on Fight Colorectal Cancer.

Nat Rev Cancer. 2026 Aug 26. doi: 10.1038/s41568-026-00965-5. Online ahead of print.

ABSTRACT

Early-onset colorectal cancer (EOCRC) among individuals under age 50 is increasing globally. Lifestyle factors such as obesity, metabolic comorbid conditions, poor diet and sedentary behaviours are linked to EOCRC, but critical gaps remain in identifying additional risk factors, with growing evidence for early-life and gut microbial-related exposures. In addition, how or when the risk factors act, individually or collectively, to initiate or promote colorectal cancer at much younger ages remains unknown. Compounding the complexity are the unique challenges of developing and implementing effective prevention strategies among younger populations. In this Roadmap, we review the progress and challenges of risk factor discovery for EOCRC, highlight opportunities for prevention and propose a transdisciplinary framework integrating population, mechanistic, behavioural and implementation sciences to accelerate causal risk factor discovery and translate insights into strategies to reverse the rising EOCRC burden. This framework, exemplified by emerging global initiatives including the Cancer Grand Challenges team PROSPECT, is broadly adaptable and intended to inspire collaborative efforts across the field. We also emphasize the critical role of patient perspectives and public engagement in shaping these efforts. With the urgency in risk factor discovery, scientists, the public and policymakers must unite to transform knowledge into life-saving solutions for future generations.

PMID:42649278 | DOI:10.1038/s41568-026-00965-5

The post Shaping the future of early-onset colorectal cancer prevention appeared first on Fight Colorectal Cancer.

Gut. 2026 Aug 25:gutjnl-2026-339088. doi: 10.1136/gutjnl-2026-339088. Online ahead of print.

NO ABSTRACT

PMID:42642216 | DOI:10.1136/gutjnl-2026-339088

The post Multi-kingdom signatures of the gut microbiome in Lynch syndrome: a prospective model for colorectal cancer evolution appeared first on Fight Colorectal Cancer.

JNCI Cancer Spectr. 2026 Aug 26:pkag080. doi: 10.1093/jncics/pkag080. Online ahead of print.

ABSTRACT

BACKGROUND: Colorectal cancer (CRC) outcomes vary by both race and ethnicity, and screening test use may contribute to this variation. We examined the association of race, ethnicity, and associated factors with CRC screening test use in a setting where financial barriers to screening are mitigated.

METHODS: Survey information was gathered from US Veteran participants (N = 50,125) when enrolled into a randomized trial comparing screening colonoscopy to annual fecal immunochemical testing (FIT) in the prevention of CRC mortality. The primary exposures of interest were the participants’ self-identified race and ethnicity, with adjustment for variables capturing access to care. Multivariable logistic regression, stratified by site and age, was used to assess the relationship between exposures of interest and prior use of any CRC screening test, prior colonoscopy, and prior fecal occult blood test (FOBT, including FIT) use.

RESULTS: Screening test use was common (N = 28,330, 56.5%) with more Veterans reporting prior FOBT (N = 20,386, 40.7%) than prior colonoscopy (N = 12,671, 25.3%). In multivariable analysis, Black participants were more likely (odds ratio (OR), 1.06; 95% confidence interval (CI) 1.01-1.12) to have had any prior screening relative to White persons and this finding was driven by more frequent FOBT use relative to White persons (OR, 1.16; 95% CI 1.10-1.23). There was no association between Hispanic ethnicity (relative to White persons) on the primary outcomes.

CONCLUSIONS: In this cohort, prior screening test use was common, with observed variation in overall test use by race, but not ethnicity. Further study of CRC screening test use in diverse populations are needed.

CLINICALTRIALS.GOV ID: NCT#05612347.

PMID:42644818 | DOI:10.1093/jncics/pkag080

The post Race, ethnicity, and prior colorectal screening test use in CONFIRM colonoscopy vs fecal immunochemical testing trial participants appeared first on Fight Colorectal Cancer.

JMIR Form Res. 2026 Aug 19;10:e86279. doi: 10.2196/86279.

ABSTRACT

BACKGROUND: Neighborhood disinvestment, characterized by built environment disrepair and deterioration, has been linked to health behaviors and outcomes, including cancer survival. However, disinvestment temporal dynamics, including time-lagged exposure estimates among colorectal cancer (CRC) cases, remain underexplored.

OBJECTIVE: This study aimed to describe and validate a spatiotemporal neighborhood audit protocol using Google Street View imagery, develop and compare predictive spatiotemporal models of neighborhood disinvestment, and examine time-lagged associations between disinvestment and CRC survival.

METHODS: We conducted 8256 virtual audits of Franklin County, Ohio, streetscapes sampled across locations and dates from 2009 to 2022 using 7 disinvestment indicators: garbage, graffiti, abandoned buildings, building conditions, yard conditions, road verge conditions, and large dumpsters. Of these, 5751 eligible location date audits were included. A neighborhood disinvestment score (NDS) was derived using item response theory. We fit spatiotemporal regression Kriging models with a simplified sum-metric covariance structure and compared two candidate models using out-of-sample root mean square prediction error (RMSPE): (1) a model incorporating major highways, waterways, and railways to define neighborhood boundaries, and (2) a traditional Kriging model allowing NDS to vary continuously across space and time. The best-fitting model was used to estimate NDS at the geocoded address and diagnosis date of 2727 CRC cases diagnosed from 2012 to 2019 and recorded within the Ohio Cancer Incidence Surveillance System. Covariates included age, sex, minoritized race-ethnicity, marital status, health insurance, and cancer stage at diagnosis (localized, regional, and distant). We built accelerated failure time models to estimate time ratios and 95% CIs for NDS averaged over 0-, 3-, 6-, 12-, 18-, and 24-month time lags. Models were adjusted for covariates. We tested stage by NDS interactions. Those alive through December 31, 2020, were right censored.

RESULTS: NDS exhibited substantial spatial but modest temporal variation, with spatial correlation measurable within 2.8 kilometers and temporal correlation up to 270 days. Traditional spatiotemporal Kriging outperformed the boundary-based model (RMSPE_traditional=0.651 vs RMSPE_boundary=0.662). NDS varied by season, with lower disinvestment scores in spring and summer compared with fall. The accelerated failure time CRC survival model indicates an interaction between NDS and stage at diagnosis for all NDS time lags tested; higher prediagnosis NDS was significantly associated with shorter survival only among those with regional and not among those with localized or distant stage at diagnosis. For example, with a 6-month prediagnosis averaged time lag, each standard deviation increase in NDS was associated with a time ratio of 0.628 (95% CI 0.436-0.904). Associations were largely identical across time lags.

CONCLUSIONS: The spatiotemporal neighborhood audit approach is feasible and efficient. NDS varies appreciably across season, was accurately estimated using regression Kriging, and time-lagged exposures from 0 to 24 months produced negligible change in the NDS-CRC survival association.

PMID:42617043 | DOI:10.2196/86279

The post Built Environment Audits Across Space and Time for Estimating Time-Varying Exposures: Cohort Study appeared first on Fight Colorectal Cancer.

Colorectal cancer is the third most common type of cancer in both men and women. Despite advancements in treatment options, there remains an urgent need to develop treatments that may improve long-term prognosis for people with metastatic colorectal cancer.  

Bevacizumab, when combined with chemotherapy, is a standard treatment for metastatic colorectal cancer. Bevacizumab targets VEGF, which reduces the blood supply to the tumor and stops the tumor acquiring the oxygen and nutrients that it needs to grow. 

Researchers are exploring whether targeting PD-1 (an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time may help the immune system find and attack the cancer cells while also slowing down tumor growth. 

About the Symbiotic-GI-03 Clinical Trial 

Pfizer’s Symbiotic-GI-03 clinical trial is evaluating a study medicine called PF-08634404 in adults with metastatic (stage IV) colorectal cancer who have not received anticancer treatment for metastatic disease and do not have BRAF V600E mutations or MSI-H/dMMR tumors. 

The study medicine is an investigational bispecific antibody designed to target both PD-1 and VEGF at the same time. These proteins can play a role in how the cancer grows and how the immune system responds to it.  

Participants will receive either the study medicine in combination with chemotherapy, or bevacizumab, in combination with chemotherapy. Participants will have a 50% chance of receiving either study treatment. This is a double-blind study, meaning neither participants nor the study team will know which study treatment is being given. 

Bottom line 

The Symbiotic-GI-03 clinical trial is evaluating whether an investigational medicine that targets both PD-1 and VEGF may work better than an approved standard treatment, bevacizumab, when combined with chemotherapy for people with metastatic colorectal cancer. 

Ask your doctor whether your tumor has been tested for key biomarkers, including RAS, BRAF V600E, and MSI/dMMR, and whether a first-line clinical trials such as Symbiotic-GI-03 may be an option for you. 

ClinicalTrials.gov: NCT07222800 

[You can also learn more at [www.PfizerStudyforCRC.com]] 

The post Hot Topic: Symbiotic-GI-03 – A novel bispecific antibody for Metastatic Colorectal Cancer appeared first on Fight Colorectal Cancer.

JAMA. 2026 Aug 10. doi: 10.1001/jama.2026.11587. Online ahead of print.

NO ABSTRACT

PMID:42574033 | DOI:10.1001/jama.2026.11587

The post Colorectal Cancer and Mortality Among Older Adults With vs Without Adenoma on Prior Colonoscopy-Reply appeared first on Fight Colorectal Cancer.

Clinical Trials Roundup

Curated by Fight CRC’s Medical Advisory Board & Research Advocacy Training and Support (RATS) team.

This month, we’re focusing on clinical trials open to patients with metastatic colorectal cancer at different stages of their treatment journey. Whether you are considering your first treatment or navigating what comes next, these summaries are designed to help patients and care partners start informed conversations with their care team.

Need help understanding clinical trials or biomarker testing? See our resources.

August 2026

1. Symbiotic-GI-03 — A Clinical Trial Researching a Potential Combination Treatment for People With Metastatic Colorectal Cancer

Biomarker Focus: RAS-mutant or RAS wild-type mCRC (excludes BRAF V600E mutation and MSI-H/dMMR tumors)
Phase / Sites: Phase III / ~210 sites worldwide
Stage: Stage IV metastatic colorectal adenocarcinoma
Recruitment Status: Recruiting
What it’s studying: Pfizer’s Phase 3 double-blind clinical trial is evaluating a potential first-line treatment for patients with metastatic colorectal cancer who have not received prior anticancer treatment for metastatic disease. The study medicine, PF-08634404, is an investigational bispecific antibody that targets both PD-1 (an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time. It is thought that by binding to these proteins, the study medicine may help the immune system find and attack the cancer cells while also potentially slowing tumor growth. Participants will receive either the study medicine in combination with chemotherapy, or bevacizumab, in combination with chemotherapy.
Why it matters: Bevacizumab combined with chemotherapy remains a common first-line standard treatment for colorectal cancer, but outcomes are still limited. Most colorectal cancers, especially those that are not MSI-H/dMMR, do not respond to immunotherapy alone. This clinical trial is researching whether the study medicine combination may improve progression-free survival (PFS) and overall survival (OS) compared to the bevacizumab combination.
Patient Tip: If you are diagnosed with metastatic colorectal cancer and have not yet started treatment, ask your doctor whether a first-line clinical trial such as Symbiotic-GI-03 may be an option for you. It is recommended that your tumor has been tested for key biomarkers, including RAS, BRAF V600E, and MSI/dMMR, as these results may help determine your eligibility for this clinical trial and others. 
ClinicalTrials.gov: NCT07222800  |  www.PfizerStudyforCRC.com 

2. INCA033890-303 — Chemotherapy + Bevacizumab With or Without INCA33890 in First-Line MSS Metastatic CRC 

Biomarker Focus: Microsatellite stable (MSS) / mismatch repair proficient (pMMR) metastatic CRC; excludes MSI-H/dMMR and BRAF V600E 
Phase / Sites: Phase III / Multicenter, including U.S. sites (Incyte-sponsored) 
Stage: Stage IV metastatic colorectal adenocarcinoma, first-line 
Recruitment Status: Recruiting 
What it’s studying: INCA033890-303 is a Phase 3 randomized, double-blind study comparing standard first-line chemotherapy plus bevacizumab with or without INCA33890, an investigational bispecific antibody targeting both PD-1 and TGFβR2 (transforming growth factor beta receptor 2). The trial enrolls patients with MSS metastatic CRC who have not previously received systemic treatment for metastatic disease. 
Why it matters: MSS colorectal cancer accounts for the large majority of metastatic cases and has historically been resistant to immunotherapy. A key reason is that TGF-beta signaling in the tumor environment actively suppresses the immune response. INCA33890 is designed to address this by blocking TGFβR2 specifically on immune cells that also express PD-1, a more targeted approach than prior TGF-beta inhibitors that caused significant toxicity. Along with Symbiotic-GI-03 and HARMONi-GI3, it is one of only three Phase 3 trials currently seeking to change how MSS mCRC is treated in the first line. 
Patient Tip: MSS is the most common biomarker profile in metastatic CRC, and historically it has meant fewer immunotherapy options. If that sounds like your diagnosis, it’s worth asking your oncologist whether this trial is available near you before you begin standard treatment. The eligibility window is first-line only, so the conversation needs to happen before chemotherapy starts. 
ClinicalTrials.gov: NCT07284849 

3. ROSETTA CRC-203 — Pumitamig + Chemotherapy vs. Bevacizumab + Chemotherapy in First-Line Metastatic CRC 

Biomarker Focus: First-line mCRC without dMMR, MSI-H, or BRAF V600E (broad MSS/RAS population)
Phase / Sites: Phase II/III / Global multicenter, including U.S. sites (Bristol-Myers Squibb / BioNTech) 
Stage: Stage IV unresectable or metastatic colorectal cancer, first-line 
Recruitment Status: Recruiting 
What it’s studying: ROSETTA CRC-203 is evaluating pumitamig, an investigational bispecific antibody targeting both PD-L1 and VEGF-A, in combination with standard chemotherapy compared against bevacizumab plus chemotherapy in patients with previously untreated, unresectable or metastatic CRC without dMMR, MSI-H, or BRAF V600E. Early Phase 2 data presented at ASCO 2026 showed promising activity, and the study is now enrolling its Phase 3 registrational cohort. 
Why it matters: Pumitamig targets PD-L1 rather than PD-1, which some researchers believe may have advantages in the tumor microenvironment of MSS CRC. The ASCO 2026 interim data generated significant interest, and enrollment into the Phase 3 portion represents an early opportunity for patients to access a drug that has not yet completed its pivotal trial. 
Patient Tip: There’s a lot happening in first-line CRC research right now, and it can feel overwhelming to keep up. Here’s a simple question worth bringing to your next appointment: ‘Are there any trials testing new combinations in first-line treatment that I might qualify for?’ Asking early, before treatment begins, is the only way to know if something like ROSETTA CRC-203 is an option for you. 
ClinicalTrials.gov: NCT07221357

4. MOUNTAINEER-03 — Tucatinib + Trastuzumab + mFOLFOX6 in HER2-Positive First-Line Metastatic CRC 

Biomarker Focus: HER2-positive, RAS wild-type first-line mCRC 
Phase / Sites: Phase III / 50+ sites globally, including U.S. 
Stage: Stage IV metastatic CRC, first-line 
Recruitment Status: Recruiting 
What it’s studying: MOUNTAINEER-03 is testing whether adding tucatinib and trastuzumab, a dual HER2-targeting combination, to standard first-line chemotherapy improves outcomes for the roughly 4% of metastatic CRC patients with HER2-amplified, RAS wild-type tumors. This Phase 3 trial compares tucatinib plus trastuzumab plus mFOLFOX6 against the current standard of care. 
Why it matters: HER2-targeted therapy has already shown meaningful benefit in patients with HER2-positive CRC who have progressed on prior lines of treatment. MOUNTAINEER-03 asks whether starting HER2 targeting earlier, at the very first line of metastatic treatment, can extend those benefits further. If positive, it would establish a new first-line standard for this biomarker subgroup. 
Patient Tip: HER2 testing is not always automatically included when you’re first diagnosed. If you’ve gotten biomarker results back and aren’t sure whether HER2 was checked, ask specifically. It’s a simple question with a potentially significant answer, especially if you’re RAS wild-type. Your care team can order the test, and it takes the guesswork out of knowing which trials you might qualify for. 
ClinicalTrials.gov: NCT05253651

5. FRUITFUL — Fruquintinib + FOLFIRI as Second-Line Treatment for Metastatic CRC 

Biomarker Focus: MSS/pMMR mCRC without BRAF V600E; prior oxaliplatin, fluoropyrimidine, and bevacizumab in first line 
Phase / Sites: Phase II / 14 U.S. sites across 9 states (SCRI-sponsored) 
Stage: Stage IV metastatic CRC, second-line 
Recruitment Status: Recruiting 
What it’s studying: FRUITFUL is a Phase II study evaluating fruquintinib, an FDA-approved oral VEGFR inhibitor, in combination with FOLFIRI chemotherapy as second-line treatment for patients with metastatic CRC. Participants must have completed first-line oxaliplatin, fluoropyrimidine, and bevacizumab-based therapy. The study is testing whether adding fruquintinib to the standard second-line FOLFIRI backbone can improve outcomes for patients progressing after first-line treatment. 
Why it matters: Fruquintinib is already FDA-approved as a later-line monotherapy for mCRC, but this trial explores whether its anti-angiogenic mechanism works even better when combined with chemotherapy earlier in the treatment sequence. For patients who have finished first-line therapy and are planning their next step, this is a meaningful opportunity to access a novel combination at a critical transition point. Sites span nine states, making this one of the more geographically accessible trials currently enrolling. 
Patient Tip: If you’ve just finished first-line treatment and your cancer has progressed, this might be exactly the kind of trial worth asking about at your next appointment. The eligibility is fairly straightforward: prior oxaliplatin-based chemo plus bevacizumab, no prior irinotecan. You don’t need a specific biomarker result to qualify, which makes it one of the more accessible trials for a broader group of patients right now. 
ClinicalTrials.gov: NCT07011576

July 2026 

1. OrigAMI-1 — Amivantamab Alone or With Chemotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type and HER2 non-amplified metastatic CRC; tumor sidedness evaluated 
Phase / Sites: Phase Ib/II / International multicenter, including U.S. sites 
Stage: Advanced or metastatic CRC, two to three prior lines of therapy 
Recruitment Status: Active, ongoing (combination chemotherapy cohorts) 
What it’s studying: OrigAMI-1 is the foundational study evaluating amivantamab, a bispecific antibody targeting both EGFR and MET, alone or combined with mFOLFOX6 or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic CRC after two to three prior lines of therapy. 
Why it matters: Updated results at ASCO GI 2026 showed over 70% of patients in the first-line combination chemotherapy subgroup responded, with most responses lasting beyond 16 months; results that launched two pivotal phase 3 studies now enrolling (OrigAMI-2 and OrigAMI-3, below). 
Patient Tip: If you have RAS/BRAF wild-type CRC and have been through several lines of treatment, ask your care team whether early-phase trials studying newer EGFR-targeting combinations are still open to enrollment.
ClinicalTrials.gov: NCT05379595 

2. OrigAMI-2 — Amivantamab + Chemotherapy vs. Cetuximab + Chemotherapy in First-Line Left-Sided RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type (KRAS, NRAS, and BRAF all wild-type); left-sided primary tumor 
Phase / Sites: Phase III / Global multicenter, including U.S. sites 
Stage: Unresectable or metastatic colorectal cancer, first-line 
Recruitment Status: Recruiting 
What it’s studying: OrigAMI-2 is comparing amivantamab plus chemotherapy (mFOLFOX6 or FOLFIRI) versus cetuximab plus chemotherapy as first-line treatment for patients with left-sided, RAS/BRAF wild-type metastatic CRC. 
Why it matters: Anti-EGFR therapy with chemotherapy is already the standard for this group, but resistance develops in most patients. Data from ESMO GI 2026 showed liquid biopsy can track that resistance; OrigAMI-2 is testing whether targeting both EGFR and MET from the start delays it. 
Patient Tip: If your tumor is RAS/BRAF wild-type and left-sided, ask your care team whether there are first-line trials testing a next-generation EGFR-targeting approach before starting standard treatment. 
ClinicalTrials.gov: NCT06662786

3. OrigAMI-3 — Amivantamab + FOLFIRI vs. Cetuximab or Bevacizumab + FOLFIRI in Second-Line RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type (KRAS, NRAS, and BRAF all wild-type) metastatic CRC 
Phase / Sites: Phase III / Global multicenter, including U.S. sites (Fox Chase Cancer Center, UCLA, and others) 
Stage: Recurrent, unresectable, or metastatic CRC after first-line chemotherapy 
Recruitment Status: Recruiting 
What it’s studying: OrigAMI-3 is evaluating subcutaneous amivantamab plus FOLFIRI versus standard second-line treatment (cetuximab or bevacizumab plus FOLFIRI) in patients with RAS/BRAF wild-type metastatic CRC who progressed on first-line chemotherapy. 
Why it matters: MET amplification is a known mechanism by which CRC develops resistance to anti-EGFR therapy after first-line treatment; amivantamab targets both EGFR and MET, and phase 1b/2 data from ASCO GI 2026 showed promising activity even in patients with prior anti-EGFR exposure. 
Patient Tip: If you have RAS/BRAF wild-type CRC and your cancer progressed on first-line therapy, ask your care team whether a second-line trial targeting both EGFR and MET could be right for you. 
ClinicalTrials.gov: NCT06750094

4. Botensilimab + Balstilimab + Fasting Mimicking Diet + Vitamin C for KRAS-Mutant MSS Metastatic CRC 

Biomarker Focus: KRAS-mutant, microsatellite stable (MSS) metastatic colorectal cancer 
Phase / Sites: Phase Ib / University of Southern California (Los Angeles, CA) 
Stage: Metastatic colorectal cancer after prior fluoropyrimidine, oxaliplatin, and irinotecan 
Recruitment Status: Recruiting 
What it’s studying: This study evaluates botensilimab and balstilimab combined with a fasting mimicking diet (a structured, plant-based, low-calorie eating plan) and high-dose intravenous vitamin C in patients with KRAS-mutant MSS metastatic CRC. 
Why it matters: ESMO GI 2026 featured three-year survival data for botensilimab plus balstilimab in MSS CRC; this trial explores whether adding metabolic strategies can extend that benefit to patients with KRAS mutations, who make up a large share of MSS metastatic CRC cases. 
Patient Tip: If your tumor is MSS and has a KRAS mutation, ask your care team whether trials combining immunotherapy with nutritional or metabolic strategies are available to you. 
ClinicalTrials.gov: NCT06336902

 5. Botensilimab + Balstilimab + SBRT for MSS CRC With Liver Metastases 

Biomarker Focus: Non-MSI-H or mismatch repair proficient (pMMR) colorectal cancer with liver metastases 
Phase / Sites: Pilot study / Massachusetts General Hospital (Boston, MA) 
Stage: Metastatic colorectal cancer with liver metastases 
Recruitment Status: Recruiting 
What it’s studying: This study evaluates botensilimab and balstilimab combined with stereotactic body radiation therapy (SBRT) to liver metastases in patients with MSS or pMMR CRC, asking whether precisely targeted radiation can activate an immune response in a setting where immunotherapy alone has been harder to get to work. 
Why it matters: The three-year ESMO GI 2026 BOT/BAL data came from patients without active liver metastases; liver involvement is associated with lower immunotherapy response rates in MSS CRC, and this trial directly addresses that gap. 
Patient Tip: If your cancer has spread to the liver, ask your care team whether trials combining radiation with newer immunotherapy drugs are available at your treatment center. 
ClinicalTrials.gov: NCT07128355 

June 2026

1. HARMONi-GI3 — Ivonescimab + mFOLFOX6 in First-Line Metastatic Colorectal Cancer

Biomarker Focus: Metastatic colorectal cancer; immunotherapy and VEGF pathway strategy
Phase / Sites: Phase III / Multicenter
Stage: Metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study compares ivonescimab plus mFOLFOX6 chemotherapy with bevacizumab plus mFOLFOX6 for patients who have not yet received systemic treatment for metastatic CRC.
Why It Matters:
First treatment decisions can feel urgent and overwhelming. This trial is studying whether combining chemotherapy with a treatment that targets both immune response and tumor blood-vessel growth may offer another first-line approach.
Patient Tip:
Ask your care team: “Do I know my MSI/MMR status, and are there any first-line clinical trials that match my diagnosis and treatment goals?”
ClinicalTrials.gov: NCT07228832

2. BAY 3771249 — KRAS G12D-Targeted Therapy for Advanced or Metastatic CRC

Biomarker Focus: KRAS G12D mutation
Phase / Sites: Phase I / Multicenter
Stage: Advanced or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating BAY 3771249, an investigational treatment being studied alone or with cetuximab for patients with advanced or metastatic CRC that has a KRAS G12D mutation.
Why It Matters:
KRAS G12D has limited targeted treatment options. This trial reflects the growing effort to develop therapies based on the exact KRAS mutation driving a person’s cancer.
Patient Tip:
Ask your care team: “Do I have a KRAS G12D mutation, and are there trials designed specifically for this subtype?”
ClinicalTrials.gov: NCT07535112

3. SGN-CEACAM5C — Antibody-Drug Conjugate Targeting CEACAM5

Biomarker Focus: CEACAM5 expression
Phase / Sites: Phase I / International study with U.S. sites
Stage: Advanced solid tumors, including colorectal cancer cohorts
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating SGN-CEACAM5C, also known as PF-08046050, in adults with advanced solid tumors, including CRC cohorts. Antibody-drug conjugates are designed to deliver treatment more directly to cancer cells with a specific target.
Why It Matters:
When standard treatments stop working, patients often want to know what other options are being studied. This trial is one example of research exploring more targeted approaches for advanced CRC.
Patient Tip:
Ask your care team: “Has my tumor been tested for markers that could help match me to a targeted therapy or antibody-drug conjugate trial?”
ClinicalTrials.gov: NCT06131840

4. EMPIRE / NSABP FC-13 — Immunotherapy for ctDNA-Positive Minimal Residual Disease

Biomarker Focus: ctDNA-positive minimal residual disease after colorectal cancer treatment
Phase / Sites: Phase II / Multicenter
Stage: Colorectal cancer after definitive surgery and chemotherapy, with ctDNA positivity
Recruitment Status: Recruiting
What It’s Studying:
EMPIRE is studying cemiplimab alone or with other immunotherapy-based treatments for people with CRC who are ctDNA-positive after surgery and chemotherapy. ctDNA is tumor DNA that can sometimes be detected through a blood test.
Why It Matters:
Many patients want to know what ctDNA results may mean for recurrence risk and next steps. This study is asking whether immunotherapy-based treatment can help delay or prevent colorectal cancer from coming back in patients with ctDNA-positive minimal residual disease.
Patient Tip:
If you have completed surgery and chemotherapy, ask your care team: “Is ctDNA testing appropriate for me, and would a positive result change my follow-up plan or clinical trial options?”
ClinicalTrials.gov: NCT07058012

5. KANDLELIT-012 — Calderasib (MK-1084) + Cetuximab + mFOLFOX6 for KRAS G12C-Mutated Colorectal Cancer

Biomarker Focus: KRAS G12C mutation
Phase / Sites: Phase III / Multicenter
Stage: Locally advanced unresectable or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating calderasib, also known as MK-1084, with cetuximab and mFOLFOX6 chemotherapy compared with mFOLFOX6 with or without bevacizumab in KRAS G12C-mutated CRC.
Why It Matters:
KRAS mutations are common in CRC, but not all KRAS mutations are the same. This trial focuses on KRAS G12C and reflects the movement toward treatments matched to specific tumor biomarkers.
Patient Tip:
If your care team says your tumor has a KRAS mutation, ask: “Which KRAS mutation do I have, and does that specific result make me eligible for any clinical trials?”
ClinicalTrials.gov: NCT06997497

6. Bonus Research Watch: CRDF-004 — Onvansertib + Chemotherapy and Bevacizumab for RAS-Mutated Metastatic Colorectal Cancer

Biomarker Focus: KRAS or NRAS mutation
Phase / Sites: Phase II / U.S. multicenter study
Stage: First-line metastatic colorectal cancer
Recruitment Status: Active, not recruiting
What It’s Studying:
CRDF-004 is studying onvansertib with standard chemotherapy and bevacizumab for adults with metastatic CRC that has a KRAS or NRAS mutation.
Why It Matters:
RAS mutations are common in metastatic CRC, and researchers continue to look for better first-line strategies. This trial is not currently recruiting, but it remains important to watch because ASCO 2026 featured interim results from CRDF-004 in first-line RAS-mutated metastatic CRC.
Patient Tip:
If your tumor has a KRAS or NRAS mutation, ask your care team: “Are there current or upcoming trials for RAS-mutated colorectal cancer that may fit my treatment plan?”
ClinicalTrials.gov: NCT06106308

May 2026

1. NCI ComboMATCH — Combination Therapy Based on Tumor Genetics 

Biomarker Focus: Actionable genetic alterations 
Phase / Sites: Screening trial supporting multiple Phase II treatment sub-studies  / U.S. NCI network 
Stage: Advanced solid tumors, including colorectal cancer when biomarker eligible 
Recruitment Status: Recruiting 
What it’s studying: ComboMATCH assigns patients to treatment combinations based on tumor genetic changes rather than cancer type alone, using a screening platform that matches patients to specific sub-studies. 
Why it matters: This builds on precision medicine by testing whether targeted drug combinations can improve outcomes for patients whose tumors have actionable alterations. 
Patient Tip: If you’ve had genomic testing, ask whether your results include an alteration that could match to a precision medicine trial. 
ClinicalTrials.gov: NCT05564377 
 

2. BASECAMP-1 — Screening Study for Future CEA-Targeted Cell Therapy 

Biomarker Focus: CEA expression, HLA type (including HLA loss of heterozygosity), tumor immune markers 
Phase / Sites: Observational screening study / U.S. sites 
Stage: Solid tumors, including colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: BASECAMP-1 screens patients for biomarkers that may determine eligibility for future CEA-targeted cell therapy studies. 
Why it matters: This expands biomarker testing beyond tumor mutations to include immune matching and cell therapy eligibility. 
Patient Tip: If you’re interested in cell therapy trials, ask whether HLA typing or CEA testing could be relevant. 
ClinicalTrials.gov: NCT04981119 

3. Onvansertib Combination Trial — KRAS-Mutant Metastatic Colorectal Cancer 

Biomarker Focus: KRAS mutation 
Phase / Sites: Phase II / U.S. and international sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates onvansertib with standard chemotherapy and bevacizumab in patients with KRAS-mutant metastatic colorectal cancer. 
Why it matters: KRAS mutations are common in CRC, but many KRAS-mutant tumors still lack effective targeted options. This study focuses on a biologically defined CRC group. 
Patient Tip: If your tumor has a KRAS mutation, ask whether the specific KRAS variant and prior treatments affect trial eligibility. 
ClinicalTrials.gov: NCT06106308 
 

4. P-MUC1C-ALLO1 — Allogeneic CAR-T Cell Therapy Targeting MUC1-C 

Biomarker Focus: MUC1-C expression 
Phase / Sites: Phase I / Includes U.S. sites 
Stage: Advanced or metastatic solid tumors, including colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates an allogeneic CAR-T cell therapy targeting MUC1-C, a tumor-associated marker expressed in several epithelial cancers. 
Why it matters: Cell therapy research in CRC is expanding, and biomarker testing may help identify patients whose tumors express targets like MUC1-C. 
Patient Tip: Ask whether your tumor testing includes protein-expression markers, not just DNA mutations. 
ClinicalTrials.gov: NCT05239143 

5. GCC19CART — CAR-T Therapy Targeting GCC in Advanced Gastrointestinal Cancers 

Biomarker Focus: GCC / guanylyl cyclase C expression 
Phase / Sites: Phase I / U.S. sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This trial evaluates CAR-T cells targeting GCC, a marker commonly associated with colorectal cancer cells. 
Why it matters: GCC-targeted cell therapy is a CRC-relevant biomarker strategy and represents a newer research direction for patients with advanced disease. 
Patient Tip: If you are exploring cell therapy options, ask whether your tumor expresses GCC or whether a GCC-targeted study is available. 
ClinicalTrials.gov: NCT05319314 

April 2026

1. JANUS Rectal Cancer Trial — Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 
Biomarker Focus: Response-adapted treatment and organ preservation strategy 
Phase / Sites: Phase II / U.S. cooperative group, multicenter 
Stage: Stage II-III / locally advanced rectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: JANUS is comparing long-course chemoradiation followed by mFOLFIRINOX versus mFOLFOX6 to improve clinical complete response and organ preservation in locally advanced rectal cancer. 
Why it matters: This study is relevant right now because it focuses on treatment intensification and organ-preservation goals in rectal cancer—an area of strong interest for patients and clinicians alike. 
Patient Tip: If you are discussing treatment before rectal cancer surgery, ask whether total neoadjuvant therapy or organ-preservation strategies may be appropriate for you. 
ClinicalTrials.gov: NCT05610163 

2. EA2201 — Immunotherapy in dMMR Stage II/III Rectal Cancer 
Biomarker Focus: Deficient mismatch repair (dMMR) / MSI-H 
Phase / Sites: Phase II / Multicenter U.S. trial 
Stage: Stage II–III locally advanced rectal adenocarcinoma 
Recruitment Status: Active, not recruiting 
What it’s studying: EA2201 is evaluating nivolumab + ipilimumab with short-course radiation in patients with MSI-H/dMMR rectal cancer, with the goal of improving response while potentially reducing the need for more intensive conventional treatment. 
Why it matters: dMMR rectal cancer is one of the clearest examples of biomarker-driven care in CRC. This trial reflects the shift toward tailoring treatment based on tumor biology. 
Patient Tip: If your tumor is dMMR or MSI-H, ask whether immunotherapy-based trials may be available before surgery. 
ClinicalTrials.gov: NCT04751370 

3. COMMIT Study — First-Line Immunotherapy Strategy in Metastatic dMMR/MSI-H Colorectal Cancer 
Biomarker Focus: dMMR / MSI-H 
Phase / Sites: Phase III / national multicenter trial 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: COMMIT is testing atezolizumab-based first-line treatment strategies, including chemotherapy/bevacizumab-containing approaches, in metastatic dMMR CRC. 
Why it matters: Although immunotherapy is already important in dMMR/MSI-H CRC, not all patients have durable benefit. COMMIT is trying to refine the best first-line approach for this population. 
Patient Tip: If you have metastatic dMMR/MSI-H CRC and are starting treatment, ask whether a first-line immunotherapy trial is an option. 
ClinicalTrials.gov: NCT02997228 

4. ERAS-007 Combination Trial in Advanced Gastrointestinal Malignancies, Including Colorectal Cancer 
Biomarker Focus: MAPK pathway / BRAF and RAS pathway signaling 
Phase / Sites: Phase Ib/II / Multicenter, including U.S. sites 
Stage: Advanced gastrointestinal malignancies, including metastatic CRC 
Recruitment Status: Completed 
What it’s studying: This study is evaluating ERAS-007, an ERK inhibitor, in combination regimens designed to interrupt downstream MAPK signaling in GI cancers, including CRC. 
Why it matters: Many CRC tumors are driven by pathway alterations that remain difficult to target directly. ERAS-007 reflects a newer strategy aimed at blocking downstream signaling to improve outcomes. 
Patient Tip: If your cancer has a BRAF or RAS-pathway alteration, ask whether downstream pathway-targeting trials may be appropriate. 
ClinicalTrials.gov: NCT05039177 

5. Nous-209 Vaccine Prevention Study in Lynch Syndrome 
Biomarker Focus: Lynch syndrome / mismatch repair deficiency risk 
Phase / Sites: Phase Ib/II / U.S.-based prevention study 
Stage: High-risk individuals with Lynch syndrome 
Recruitment Status: Active, not recruiting 
What it’s studying: This study is evaluating the Nous-209 vaccine strategy for cancer prevention in Lynch syndrome carriers at elevated risk for colon and other Lynch-associated cancers. 
Why it matters: This is a prevention-focused trial rather than a treatment trial, but it is highly relevant to colorectal cancer because it aims to reduce future cancer risk in a well-defined high-risk population. 
Patient Tip: If you or your family members have Lynch syndrome, ask whether prevention studies or surveillance-focused research may be appropriate. 
ClinicalTrials.gov: NCT05078866 

March 2026

1. ARPA-H ADAPT Oncology Platform – Colorectal Cohort 

Biomarker Focus: Real-time biomarker integration and adaptive trial infrastructure 
Phase / Sites: Early research initiative / United States 
Stage: Colorectal cancer (see eligibility criteria in protocol) 
Recruitment Status: Not yet recruiting 
What it’s studying: This ARPA-H supported initiative is part of the ADAPT oncology platform, designed to modernize how cancer clinical trials are conducted. The platform integrates advanced biomarker monitoring, coordinated data systems, and adaptive treatment strategies to accelerate therapeutic development in CRC and other cancers. 
Why it matters: Rather than testing a single drug, this national investment focuses on transforming the clinical trial system itself — potentially speeding up how promising treatments move from concept to clinic. 
Patient Tip: Even if enrollment hasn’t begun, ask your care team about upcoming federally funded research programs that may open new opportunities. 
ClinicalTrials.gov: NCT07318389

2. Molecularly Guided Therapy Based on Tumor Genetics: NCI-MATCH 

Biomarker Focus: Actionable genetic mutations 
Phase / Sites: Phase 2 / Nationwide (NCI-sponsored) 
Stage: Advanced solid tumors, including colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: NCI-MATCH assigns treatment based on specific genetic mutations found in a tumor rather than the cancer’s location in the body. Patients with colorectal cancer whose tumors harbor actionable mutations may be matched to targeted therapies designed for those alterations. 
Why it matters: This national precision-medicine trial helped redefine how we think about treatment selection. Instead of a one-size-fits-all approach, MATCH reflects a shift toward therapy guided by tumor biology. 
Patient Tip: If you’ve had comprehensive genomic testing, ask whether your tumor’s mutations may qualify you for a MATCH sub-study. 
ClinicalTrials.gov: NCT02465060

3. COBRA Trial: ctDNA-Guided Predictor in Stage IIA 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase 2/3 / U.S. cooperative groups 
Stage: Stage II colon cancer 
Recruitment Status: Active 
What it’s studying: The COBRA study evaluates whether ctDNA testing after surgery can identify patients who truly need chemotherapy and who may safely avoid it. 
Why it matters: This study reflects the growing role of blood-based biomarkers in guiding adjuvant therapy, with the goal of reducing overtreatment while maintaining excellent outcomes. 
Patient Tip: If you have stage II colon cancer, ask whether ctDNA testing is appropriate for you and whether participation in a biomarker-guided trial is an option. 
ClinicalTrials.gov: NCT04068103

4. SWOG S2107: Immunotherapy Strategies in MSS Metastatic CRC 

Biomarker Focus: Microsatellite stable (MSS) and BRAF V600E mutation 
Phase / Sites: Phase 2 / National cooperative group (SWOG) 
Stage: Previously treated metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This study is testing whether adding nivolumab (immunotherapy) to encorafenib + cetuximab improves outcomes in BRAF V600E/MSS metastatic CRC. 
Why it matters: Approximately 85–90% of colorectal cancers are MSS. Expanding immunotherapy strategies for this population remains one of the most urgent research priorities in CRC, and to a population that historically does not benefit from single-agent checkpoint inhibitors. 
Patient Tip: If you’ve been told your tumor is MSS and that immunotherapy alone is unlikely to work, ask whether combination immunotherapy trials are available at your treatment center. 
ClinicalTrials.gov: NCT04963283 

5. CIRCULATE-US (NRG-GI008) — ctDNA-Guided Adjuvant Strategy in Stage II/III 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase II/III / North America (NRG Oncology) 
Stage: Stage II and III (resected) colon cancer 
Recruitment Status: Recruiting 
What it’s studying: This randomized study evaluates whether post-surgical ctDNA testing can guide escalation or de-escalation of chemotherapy in patients with stage II or III colon cancer. Patients who test ctDNA-positive may receive intensified therapy, while those who test ctDNA-negative may receive less intensive treatment. 
Why it matters: ctDNA is emerging as a precision tool to detect minimal residual disease and personalize adjuvant therapy decisions. 
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask whether ctDNA testing or enrollment in a ctDNA-guided trial is appropriate for you. 
ClinicalTrials.gov: NCT05174169 

February 2026

1. BRAFTOVI® + Cetuximab + FOLFIRI — New Triplet Regimen for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Multinational (Pfizer-sponsored)
Stage: Metastatic (mCRC)
Recruitment Status: Active, not recruiting
What it’s studying: This study evaluates the combination of encorafenib + cetuximab + FOLFIRI in patients with previously treated, BRAF V600E-mutated metastatic CRC.
Findings: Results from ASCO GI 2026 show a significant increase in overall response rates (ORR) and progression-free survival compared to historical controls.
Why it matters: Offers a promising targeted therapy option earlier in the treatment journey for patients with BRAF-mutant CRC.
Patient Tip: If your tumor is BRAF V600E-positive and you’ve been previously treated, ask your care team about this combination.
ClinicalTrials.gov: NCT04607421

2. CIRCULATE-North America (NRG-GI008) — ctDNA-Guided Adjuvant Therapy in Stage II/III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase II/III / North America (NRG Oncology)
Stage: Stage II and III (resected)
Recruitment Status: Recruiting
What it’s studying: This randomized trial evaluates whether ctDNA testing after surgery can guide the need for adjuvant chemotherapy in patients with stage II or III colon cancer. Patients with detectable ctDNA may receive intensified treatment, while ctDNA-negative patients may avoid unnecessary chemotherapy.
Presented: ASCO GI 2026
Why it matters: ctDNA is emerging as a precision tool for assessing minimal residual disease (MRD). This trial could help patients avoid overtreatment—or identify recurrence risk earlier.
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask if ctDNA testing might inform your follow-up care plan.
ClinicalTrials.gov: ASCO Abstract: NRG-GI008

3. KEYNOTE-975 Subanalysis — Pembrolizumab in dMMR/MSI-H mCRC

Biomarker Focus: dMMR / MSI-H
Phase / Sites: Phase 3 / Global
Stage: Metastatic
Recruitment Status: Ongoing
What it’s studying: Examining the efficacy of pembrolizumab as a first-line treatment for dMMR/MSI-H metastatic CRC.
Findings: Durable responses reported in previously untreated patients, including those with comorbidities and older age groups.
Why it matters: Validates immunotherapy as a frontline option in dMMR CRC—not just for ideal candidates.
Patient Tip: If your tumor is MSI-H or dMMR, ask if you qualify for first-line immunotherapy.
ClinicalTrials.gov: NCT04003636

4. BEACON-Lite Cohort A — Real-World Evaluation of Triplet Therapy in BRAF CRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Expanded access
Stage: Metastatic
Recruitment Status: Closed to new participants
What it’s studying: A cohort evaluating encorafenib + cetuximab + chemotherapy in patients not eligible for the original BEACON trial.
Findings: Preliminary real-world data shows efficacy in older patients and those with comorbidities.
Why it matters: Supports more inclusive criteria for accessing promising triplet regimens.
Patient Tip: If you were previously excluded from BRAF-targeted trials, ask if real-world data may now support this approach.
ClinicalTrials.gov: NCT02928224

January 2026

1. BREAKWATER Trial — Triplet Therapy Sets New Standard for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 3 / Multi-national
Stage: Stage IV (metastatic)
Recruitment Status: Completed (Phase 3)
What it’s studying: Encorafenib + cetuximab + FOLFIRI vs chemotherapy in first-line mCRC
Findings: PFS nearly doubled (12.8 vs 7.1 months); OS improved to 30.3 vs 15.1 months
Why it matters: A new triplet could replace chemo as the standard for BRAF-mutated mCRC
Patient Tip: If you have BRAF V600E-mutant CRC and are starting first-line treatment, ask whether this triplet regimen is being considered.
ClinicalTrials.gov: N/A

2. ATOMIC Trial — Atezolizumab + Chemo in Stage III dMMR CRC

Biomarker Focus: Mismatch repair deficiency (dMMR / MSI-H)
Phase / Sites: Phase 3 / Multi-center
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: mFOLFOX6 with or without atezolizumab after surgery in stage III colon cancer
Findings: 3-year disease-free survival improved to 86.4% vs 76.6%
Why it matters: May change adjuvant therapy for early-stage dMMR CRC
Patient Tip: If your tumor is MSI-H/dMMR and you’re receiving adjuvant chemo, ask whether immunotherapy was considered or studied in your care setting.
ClinicalTrials.gov: NCT02912559

3. IVX037 + Sintilimab in MSS CRC — RNA Virus Therapy for IO-Resistant Tumors

Biomarker Focus: Microsatellite stable (MSS), KRAS mutations
Phase / Sites: Phase 1 / Single site (expansion)
Stage: Stage IV (refractory)
Recruitment Status: Expansion underway (Phase 1a complete)
What it’s studying: A bio-selected, receptor-targeted oncolytic RNA virus (IVX037) injected into tumors, combined with anti-PD-1 sintilimab
Findings: Disease control in patients with MSS and KRAS G12D CRC; early immune activation observed
Why it matters: One of the first intratumoral viral therapies showing benefit in MSS CRC: a population typically unresponsive to immunotherapy
Patient Tip: If your tumor is MSS and you’ve exhausted chemo options, ask your care team about clinical trials exploring novel immunotherapy combinations or virus-based therapies.
ClinicalTrials.gov: N/A

4. DYNAMIC-III Trial — ctDNA-Guided Escalation in Stage III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase 2 / Australia
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: Use of post-surgical ctDNA to guide chemotherapy intensity
Findings: Escalation based on ctDNA positivity improved outcomes; negative ctDNA patients avoided unnecessary chemo
Why it matters: Further validates ctDNA as a tool for adjuvant therapy decisions
Patient Tip: If you’ve had surgery for stage III CRC, ask if ctDNA testing could help tailor your chemotherapy plan.
ClinicalTrials.gov: NCT03803553

5. Tumor-Agnostic ADC Use in CRC – Real-World Data on KRAS G12C and HER2+ Subtypes
Biomarker Focus: KRAS G12C, HER2, and ADC-responsive profiles
Phase / Sites: Retrospective / Multiple centers
Stage: Stage IV (refractory)
Recruitment Status: Retrospective analysis of real-world patients (not an interventional trial)
What it’s studying: Outcomes among CRC patients treated with tumor-agnostic antibody-drug conjugates (ADCs) in third-line or later settings
Findings: HER2+ and KRAS G12C patients experienced stable disease or prolonged progression-free survival with investigational ADCs
Why it matters: Highlights the transition of novel ADCs from trials to practice and underscores the importance of biomarker matching in refractory mCRC
Patient Tip: If you’ve already tried standard treatments, ask your provider about biomarker testing for targets like HER2 or KRAS G12C, which may open access to novel ADC-based strategies through expanded access or real-world use.
ClinicalTrials.gov: N/A

The post On Our Radar: August 2026 Clinical Trials Roundup appeared first on Fight Colorectal Cancer.

Ann Surg Oncol. 2026 Aug 3. doi: 10.1245/s10434-026-20210-5. Online ahead of print.

ABSTRACT

INTRODUCTION: Peritoneal carcinomatosis from lower gastrointestinal malignancies causes debilitating intra-abdominal complications, including bowel obstruction, ascites, and biliary/ureteral obstruction. Guidelines addressing palliative cytoreductive surgery (CRS) in patient’s ineligible for curative resection remain limited.

METHODS: Patients who underwent CRS for appendiceal cancer (AC)- or colorectal cancer (CRC)-related carcinomatosis not amenable to complete cytoreduction at one referral center (2004-2025) were retrospectively reviewed. Tumor grade was dichotomized into low- (well- and well-to-moderately differentiated ACs) versus high-grade (moderately or poorly differentiated/signet ring ACs, all CRCs). Descriptive statistics summarize patient demographics. Carcinomatosis-related complication-free (CRCFS), obstruction-free (OFS), ascites-free (AFS), and overall survival (OS) were estimated by using the Kaplan-Meier method.

RESULTS: A total of 131 patients underwent palliative CRS. The most common reasons for incomplete cytoreduction were high tumor burden/multiple unresectable areas 62 (47%), portal 20 (15%), small bowel 19 (14%), or pelvic 17 (13%) disease. Common palliative procedures included omentectomy 86 (66%), hyperthermic intraperitoneal chemotherapy 63 (48%), bowel resection 63 (48%), gastrostomy tube/gastropexy 60 (46%), and intestinal bypass 27 (20%). Twenty-two (17%) patients had major complications, and median length of stay was 11 days (IQR 9-14). Median CRCFS, OFS, AFS, and OS were 11, 16, 62, and 13 months for high-grade versus 36, NR, NR, and 37 months for low-grade tumors. The strongest predictor of shortened CRCFS, OFS, AFS, and OS was high-grade histology.

CONCLUSIONS: Palliative CRS for incompletely resectable carcinomatosis is associated with prolonged OFS and AFS for patients with low-grade histology. Palliative surgical intervention should be considered in carefully selected patients.

PMID:42547753 | DOI:10.1245/s10434-026-20210-5

The post Role of Palliative Cytoreductive Surgery for Patients with Incompletely Resectable Peritoneal Carcinomatosis from Lower Gastrointestinal Cancers appeared first on Fight Colorectal Cancer.

Clin Colorectal Cancer. 2026 Jul 14:S1533-0028(26)00050-2. doi: 10.1016/j.clcc.2026.07.003. Online ahead of print.

NO ABSTRACT

PMID:42547373 | DOI:10.1016/j.clcc.2026.07.003

The post Time to Double Down: Dual Immunotherapy as the Best Bet for Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer appeared first on Fight Colorectal Cancer.